HIT · Health In Tech, Inc.
AI read · Bad for HIT
The AI's read
The two rule failures could put HIT's Nasdaq listing at risk. The board and audit committee do not meet Nasdaq's independence rules, and the stock has stayed below $1 for 30 business days. Nasdaq says trading can continue during the cure periods. HIT expects to add an independent director after its November 10, 2026 meeting, and it has until April 12, 2027, to close at $1 or more for 10 straight business days. Those steps are not complete, so the listing concerns outweigh the extra time to fix them.